Home
Life Sciences

Sector: Life Sciences

Huawei, Intel among big firms selling patents in June-recorded transactions

Two deals could bring NPE risk but others stem from bankruptcies, buying and selling of business units and company product collaborations

Historic moment as UPC hands down two full decisions within 24 hours of each other

The Unified Patent Court has handed patentees a win and a loss in its first on-the-merits rulings

Pharma patent litigation highlights in Southeast Asia in early 2020s

Rouse highlights some of the most important pharma patent decisions issued by Southeast Asian courts in the past four years

Latest content

Teva to be investigated by FTC, ramping up scrutiny of Orange Book listings

Antitrust challenges against pharma patent strategies continue to escalate

02 July 2024

UK court fast-tracks patent trials ahead of parallel UPC hearings

But desire to influence Unified Patent Court decision unlikely to be enough to justify UK expedition requests

01 July 2024

Federal Circuit’s latest skinny label decision is another headache for generics

Appellate court hands down guidance on induced infringement cases

28 June 2024

UPC’s first ever pharma preliminary injunction decisions add to patentees’ losing streak

Alexion Pharmaceuticals denied PI requests against biosimilar eculizumab producers Amgen and Samsung Bioepis

27 June 2024

How new technologies are reshaping IP and deal terms in life sciences transactions

Each speciality comes with its own challenges and risks which shape how deals are negotiated and structured – and there is no ‘one-size fits all’ approach

26 June 2024

Building a robust trade secret strategy in China

Featured in The Guide to Life Sciences: Key issues for senior life sciences executives 2024

Life sciences companies should look to China’s recent legislation and court decisions as a framework to build a robust China IP strategy that integrates both patents and trade secrets.

24 June 2024

IP experts remain positive in the face of changes to the global life sciences landscape

AI, counterfeits and legislative overhauls are changing the game but contributors to the IAM Guide to Life Sciences offer strategic steps to help companies stay one step ahead

24 June 2024

A closer look at the latest PTAB estoppel developments

Featured in The Guide to Life Sciences: Key issues for senior life sciences executives 2024

As courts continue to shape and refine the metes and bounds of PTAB estoppel on subsequent invalidity challenges before the district courts and the USPTO, patent challengers should carefully consider their strategies for invalidating biotechnology and pharmaceutical patents.

24 June 2024

What rights holders need to know about patent-term extensions in Europe

Featured in The Guide to Life Sciences: Key issues for senior life sciences executives 2024

24 June 2024

Mexico: regulatory certainty for biosimilars on the horizon

Featured in The Guide to Life Sciences: Key issues for senior life sciences executives 2024

The challenges that innovators face when enforcing and defending their rights depend on how developed the regulatory framework is, and the courts’ approach to patent cases. Against this backdrop, the biosimilar industry is tackling regulatory uncertainties and Mexico's 2024 elections could prove pivotal when it comes to developing a strategy to combat these issues.

24 June 2024

Unlock unlimited access to all IAM content